Clinical Trial Update: Naltrexone/Bupropion Cardiovascular Outcomes Study [Phase 4]

View source ↗

Summary

Phase 4 cardiovascular outcomes trial of naltrexone/bupropion for obesity was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Obesity

Drugs mentioned

• Naltrexone/Bupropion (Contrave) (Naltrexone; Bupropion)

Snippet

Sponsor: Orexigen Therapeutics, Inc | Conditions: Obesity, Cardiovascular Diseases | Phase 4 | Status: TERMINATED | Results posted: 2017-02-27